Immix Biopharma (Nasdaq: IMMX) Email Formats

Biotechnology Research • Los Angeles, California, United States • 21-50 Employees

Immix Biopharma (Nasdaq: IMMX) Email Formats

Immix Biopharma (Nasdaq: IMMX) uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@immixbio.com), used 82.4% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@immixbio.com	82.4%
{first initial}.{last name}	j.doe@immixbio.com	11.8%
{first initial}	j@immixbio.com	5.9%

Key Contacts at Immix Biopharma (Nasdaq: IMMX)

Ilya Rachman

Co-Founder & Ceo

Mel Davis-Pickett

Director, Head Of Technical Development

Jane Buchan

Independent Director

Gabriel Morris

Member Board Of Directors

Dean Leonardi

Associate Director, Lead Biostatistician

Company overview

Headquarters	Los Angeles, California, United States
Phone number	+13106518041
Website	immixbio.com
SIC	873
Founded	2012
Employees	21-50
Socials

About Immix Biopharma (Nasdaq: IMMX)

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases. Our lead cell therapy is FDA IND cleared next generation CAR-T NXC-201, currently being evaluated in our ongoing Phase 1b/2 NEXICART-1 (NCT04720313) clinical trial, initiated in February 2021. NXC-201 has the potential to be the world’s first “Single-Day CRS” CAR-T (CRS median onset day 1, median duration 1 day), enabling the potential for a faster return home for patients and supporting ongoing expansion into autoimmune indications. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and ODD by the European Commission (EMA) in AL Amyloidosis. Learn more at www.immixbio.com and www.BeProactiveInAL.com.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Manager

Director

Employees by Department

Immix Biopharma (Nasdaq: IMMX) has 12 employees across 7 departments.

Departments

Number of employees

Funding Data

Explore Immix Biopharma (Nasdaq: IMMX)'s funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2020-01-17	1	N/A
2024-03-05	14	$15,000,000
2025-10-08	14	$9,100,000

Funding Insights

$24,100,000

Total funding amount

$9,100,000

Most recent funding amount

Number of funding rounds

Immix Biopharma (Nasdaq: IMMX) Tech Stack

Discover the technologies and tools that power Immix Biopharma (Nasdaq: IMMX)'s digital infrastructure, from frameworks to analytics platforms.

Vimeo

Video players

Swiper

JavaScript libraries

jQuery UI

JavaScript libraries

Hello Elementor

WordPress themes

Elementor

Page builders

Microsoft 365

jQuery Migrate

JavaScript libraries

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

LiteSpeed

Web servers

Apple iCloud Mail

Webmail

HTTP/3

Miscellaneous

Frequently asked questions

Immix Biopharma (Nasdaq: IMMX) is located in Los Angeles, California, US.

You can reach Immix Biopharma (Nasdaq: IMMX) at +13106518041.

Immix Biopharma (Nasdaq: IMMX) was founded in 2012, making it 14 years old. The company has established itself as a significant player in its industry over this time.

Immix Biopharma (Nasdaq: IMMX) has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Immix Biopharma (Nasdaq: IMMX) has raised a total of $24,100,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Immix Biopharma (Nasdaq: IMMX)

Ilya Rachman

Co-Founder & Ceo

Mel Davis-Pickett

Director, Head Of Technical Development

Jane Buchan

Independent Director

Gabriel Morris

Member Board Of Directors

Dean Leonardi

Associate Director, Lead Biostatistician

4.8